Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Fragile X Syndrome
NCT03862950Phase 2Completed
- Sponsor
- University of Alberta
- Start
- May 2019
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of metformin in Fragile X syndrome (FXS), sponsored by University of Alberta. Primary endpoint: Expressive Language Sampling Number of Different Words at 16 weeks. Started May 2019; status: completed.
02
Drugs
metformin
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT03862950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862950.